Gastroenterology Medication Date: Patient Name: Date of Birth:			Fax Referral To: 877-438-9380	Specialty Infusion Services		
PREVIOUS ADMINISTRATION						
Please provide the following information: Last Infusion Da				Next Infusion Date:		
			DIAGNOSIS			
DescriptionO Crohn's DiseaseO Ulcerative ColitisICD-10 CodeO K50.0O K51.9						
OTHER REQUIRED DOCUMENTATION (Please attach documents as needed)						
This signed order Patient Demograp		○ History and Physical ance Information	<ul> <li>Tysabri Touch Authorization</li> <li>TB and Hep B Documentation</li> <li>Clinical progress notes, lab work (including most recent renal function tests and any other tests supporting primary diagnosis)</li> </ul>			
CLINICAL INFORMATION (Please attach all clinical information, lab results and other medical history documents)						
Patient weight: Line Access:	Lb PIVPI	0	aches Allergies: b-Q			
MEDICATION	DOSE	DIRECTIONS		LAB & ANCILLARY ORDERS	REFILLS	
O Entyvio	300mg vial	- 0	r over 30 minutes at week 0, 2, and 6 g IV over 30 minutes every 8 weeks	Baseline Liver Enzymes TB Skin Test		
C Remicade	100mg vial		V over 2-3 hours at week 0, 2, and 6 kg IV over 2-3 hours every 8 weeks	TB Skin Test Hepatitis B protocol		
<ul> <li>Inflectra</li> </ul>	100mg vial	0	V over 2-3 hours at week 0, 2, and 6 kg IV over 2-3 hours every 8 weeks	TB Skin Test Hepatitis B protocol		
C Renflexis	100mg vial		V over 2-3 hours at week 0, 2, and 6 kg IV over 2-3 hours every 8 weeks	TB Skin Test Hepatitis B protocol		
🔘 Stelara	<ul> <li>○ 130mg</li> <li>vial</li> <li>○ 90mg PFS</li> </ul>	<ul> <li>Initiation - &lt;55kg 260mg; 55</li> <li>infusion over 60 minutes x 1</li> <li>Maintenance - Inject 90mg 5</li> </ul>		TB Skin Test		
🔿 Tremfya	<ul> <li>○ 100mg</li> <li>SmartJect</li> <li>○ 100mg PFS</li> </ul>	<ul> <li>Initiation - Infuse 200mg IV</li> <li>Maintenance - Subcutaneou preferred pharmacy</li> </ul>	' at week 0, 4 and 8 Is maintenance doses must be sent to patient's	TB Skin Test cBS with Diff		
🔘 Tysabri	300mg vial	Infuse 300mg IV over 60 mi	nutes every 4 weeks			
Premedication(s)         Diphenhydramine 25-50 mg po - 25mg #2 per dose         Acetaminophen 325-650 mg po - 325mg #2 per dose         Methylprednisolone       mg IV over         Other:			Ancillary orders will include: NaCl 0.9% 5-10ml IV before and after infusion Heparin 10 units/ml 3-5ml IV after infusion for peripheral access and PRN Heparin 100 units/ml 3-5ml IV after infusion for central IV access and PRN All infusion supplies necessary to administer the medication Anaphylaxis Kit			
			dically necessary. Presriber's Signa th to serve as my prior authorization agent with medical a			
Physician signature:			Date:			
Physician name: (	Please print)					
Phone: Fax:			License #:	License #: NPI #:		
outreach to the prescriber. Th permitted or required to do s prohibited. If you have receive Drug names are the property information contained thereir rights reserved. "The content	his information is inter o by law or regulation ed this information in of their respective own by any other person is not intended to diag offer personalized adv	nded only for the use of the individual or et . If you are not the intended recipient, you error, please notify the sender immediately ners. The information contained in this docu is not authorized. If you are not the intende gnose, treat, or cure any medical condition. vice based on a person's medical history ar	uch as e-prescribing, state specific prescription form, fax la ntity named above. The authorized recipient of this inform are hereby notified that any disclosure, copying, distribut and arrange for the return or destruction of these docum ment may be confidential and is intended solely for the u ed recipient, please notify us immediately by calling 800-6 . Individual experiences with infusion therapy may vary, an nd condition. By accessing this content, you agree to holo	mation is prohibited from disclosing this information to tion, or action taken in reliance on the contents of the: enets. This prescription may be filled out at a pharmacy se of the named recipient(s). Access, copying or re-use a 65-2850 or faxing back to the originator.@2024 Continuin nd healthcare decisions should always be made in consu	any other party unless se documents is strictly of the patient's choice. of the document or any uumRx Services, Inc. All ultation with a qualified	